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Protocol
AbstrACt
Introduction The antiplatelet therapy in the primary 
prevention of cardiovascular disease in patients with 
chronic obstructive pulmonary disease (APPLE COPD-
ICON2) trial is a prospective 2×2 factorial, double-blinded 
proof-of-concept randomised controlled trial targeting 
patients with chronic obstructive pulmonary disease 
(COPD) at high risk of cardiovascular disease. The 
primary goal of this trial is to investigate if treatment with 
antiplatelet therapy will produce the required response 
in platelet function measured using the Multiplate test in 
patients with COPD.
Methods and analysis Patients with COPD are screened 
for eligibility using inclusion and exclusion criteria. Eligible 
patients are randomised and allocated into one of four 
groups to receive aspirin plus placebo, ticagrelor plus 
placebo, aspirin plus ticagrelor or placebo only. Markers of 
systemic inflammation, platelet reactivity, arterial stiffness, 
carotid intima-media thickness (CIMT), lung function and 
quality of life questionnaires are assessed. The primary 
outcome consists of inhibition (binary response) of aspirin 
and ADP-induced platelet function at 6 months. Secondary 
outcomes include changes in inflammatory markers, CIMT, 
non-invasive measures of vascular stiffness, quality of 
life using questionnaires (EuroQol–five dimensions–five 
levels of perceived problems (EQ5D-5L), St. George’s 
COPD questionnaire) and to record occurrence of repeat 
hospitalisation, angina, myocardial infarction or death 
from baseline to 6 months. Safety outcomes will be rates 
of major and minor bleeding, forced expiratory volume in 
1 s, forced vital capacity and Medical Research Council 
dyspnoea scale.
Ethics and dissemination The study was approved by 
the North East-Tyne and Wear South Research Ethics 
Committee (15/NE/0155). Findings of the study will be 
presented in scientific sessions and published in peer-
reviewed journals.
trial registration number ISRCTN43245574; Pre-results.
IntroduCtIon 
Chronic obstructive pulmonary disease 
(COPD) is a significant burden on the 
National Health Service. It is estimated to 
affect 3 million people within the UK, with 
approximately 2 million patients remaining 
undiagnosed.1 We previously examined the 
evidence for increased cardiovascular (CV) 
disease risk in patients with COPD. We have 
reported possible mechanisms linking these 
two chronic conditions, discussed possible 
predictors or markers of poor outcomes 
among patients diagnosed with both COPD 
strengths and limitations of this study
 ► Our study will consist of patients who have not 
been previously targeted in clinical cardiovascular 
research.
 ► We therefore hope to gather as much information 
as possible regarding the cardiovascular status of 
these high-risk patients with chronic obstructive 
pulmonary disease (COPD) in this proof-of-concept 
trial.
 ► Our study consists of patients with COPD who have 
not previously been diagnosed with coronary artery 
disease (CAD) and yet are at higher risk of CAD, 
myocardial infarction and excess mortality.
 ► The findings of this study will provide us with de-
tailed information regarding this patient cohort that 
will enable us to very carefully plan a future large-
scale multicentre primary prevention study using 
antiplatelet therapy in patients with COPD at risk of 
future cardiovascular events.
 ► This trial is not powered to evaluate hard end points 
such as death or myocardial infarction.
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and coronary artery disease (CAD), and the therapeutic 
options aimed at reducing CV risks associated with 
COPD.2 
The prevalence of CAD in patients with COPD has been 
estimated at 10%–38%,3–8 with 20%–50% of mortality in 
COPD being related to CV causes.9 10 A retrospective data-
base analysis of pooled data from 2007 to 2010 in the USA 
has revealed a higher prevalence of cerebrovascular and 
CV disease in patients with COPD compared with subjects 
with no COPD, with a short-term risk of 35.8% in subjects 
with COPD compared with 18.9% in control subjects.11 In 
the Evaluation of COPD Longitudinally to Identify Predic-
tive Surrogate Endpoints (ECLIPSE) study, Williams et al 
demonstrated that coronary artery calcium (CAC) score 
evaluated on CT scan was higher in patients with COPD 
than smokers or non-smokers. The presence of CAC is 
associated with increased dyspnoea, reduced exercise 
capacity and increased mortality reiterating the fact that 
the presence of CAD in patients with COPD is associated 
with poor clinical outcomes.12
Beyond the well-known shared risk factors between 
COPD and CAD (smoking, low socioeconomic status and 
sedentary lifestyle), several other mechanisms have been 
thought to contribute to this increased CV risk. Among 
these are increased platelet activation and aggregation in 
patients with COPD, as activated platelets play a key role 
in the pathogenesis of atherothrombosis. The formation 
of monocyte-platelet aggregates is a sensitive marker of 
platelet activation and it takes place in the early stages 
of the process of development of atherothrombosis.13 
Patients with COPD have been shown to have an increased 
level of platelet-monocytes aggregates compared with 
control subjects, with further increase in the level of these 
aggregates during an acute exacerbation.14
Recently, the Study to Understand Mortality and 
Morbidity (SUMMIT) trial evaluated whether inhaled 
treatment with a combined treatment of the corticoste-
roid, fluticasone furoate and the long-acting β-agonist, 
vilanterol could improve survival compared with placebo 
in patients with moderate COPD and heightened CV risk. 
In this large trial of 16 485 participants, treatment with 
fluticasone furoate and vilanterol did not affect mortality 
or CV outcomes. This suggests that treatments targeting 
inflammation in the lung and attempting to improve lung 
function do not convey any beneficial effects on overall 
mortality and CV outcomes. Thus, ongoing clinical 
research is required to evaluate strategies to improve CV 
outcomes in this high-risk patients with COPD in whom 
the CVD burden is very high.15–17
Antiplatelet therapy (APT) plays a crucial part in the 
management of acute coronary syndrome (ACS).18 
Recent reports have shown that inhibition of the puri-
nergic receptor P2Y12 is associated with a marked reduc-
tion in platelet reactivity, and has anti-inflammatory 
effects.19 The effects of P2Y12 receptor antagonists beyond 
platelet inhibition have been previously reviewed in 
detail.20 In an analysis from the Platelet Inhibition and 
Patient Outcomes (PLATO) trial, fewer on-treatment 
pulmonary adverse events (AEs) occurred in the tica-
grelor group compared with the clopidogrel group, 
with fewer deaths following these AEs, particularly in 
those who remained on study medication 3 days after AE 
onset.21 Prior data suggest that ticagrelor also influences 
host defence against bacterial lung infection through 
adenosine-mediated neutrophil chemotaxis.22 Further-
more, recent studies demonstrated the safe use of tica-
grelor in patients with mild-to-moderate COPD with very 
low rates of bronchospasm.23 There was a similar efficacy 
benefit and safety profile of ticagrelor compared with 
clopidogrel with low rates of discontinuation of ticagrelor 
due to dyspnoea.24 Importantly, blocking ADP receptors 
with antagonists protects against cigarette smoke-induced 
lung inflammation and development of emphysema in 
mice suggesting a potential additional benefit of ADP 
blockade. A previous observational study showed that the 
use of aspirin or clopidogrel in patients with acute exac-
erbations of COPD correlated with a reduction in 1-year 
mortality (OR 0.63; 95% CI 0.47 to 0.85, p=0.003).25
These additional effects of P2Y12 inhibitors offer the 
potential for primary prevention in a population at 
high risk for CV disease such as patients with COPD by 
reducing inflammation with resultant reduction in CV 
risk. However, our unpublished database review of 24 000 
patients with COPD show very few patients with COPD 
are receiving APT treatment despite the association of 
increased platelet activity, inflammation and increased 
CV events in patients with COPD. Although APT using 
aspirin and ticagrelor (a novel potent antiplatelet agent 
P2Y12 receptor antagonist) is now used in the manage-
ment of patients with ACS, its role in reducing AEs among 
patients with COPD at risk of cardiac events without 
ACS has not been previously evaluated in randomised 
controlled trials. Therefore, we undertook this proof-of-
concept trial to evaluate the effect of APT (aspirin, tica-
grelor) on platelet function and explored its effect on 
the inflammatory markers in patients with COPD with no 
history of CAD.
HypotHEsIs
Treatment with antiplatelet drugs will result in signifi-
cant platelet inhibition, improvement in inflammatory 
markers of CV disease burden and lung function in 
patients with COPD.
prIMAry objECtIvE
To investigate if treatment with APT will produce the 
required response in platelet function measured using 
the Multiplate test in patients with COPD.
sECondAry objECtIvEs
The secondary objectives of the APPLE COPD trial 
consists of the following:
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1. To investigate if treatment with APT will lead to re-
duction in inflammatory marker levels including fi-
brinogen, high-sensitivity C reactive protein (hsCRP), 
tumour necrosis factor-alpha (TNF-α), interleukin-6 
(IL-6), myeloperoxidase (MPO).
2. To investigate if treatment with APT will lead to im-
provement in spirometry (forced expiratory volume in 
1 s (FEV1) and forced vital capacity (FVC)), vascular 
stiffness and carotid intima-media thickness (CIMT).
3. To investigate if treatment with APT will lead to im-
provement in quality of life.
4. To record AEs including breathlessness, occurrence of 
repeat hospitalisation, angina, myocardial infarction 
or death from baseline to 6 months following treat-
ment with aspirin and/or ticagrelor in patients with 
COPD.
MEtHods
The APPLE-COPD trial is a 2×2 factorial, randomised, 
controlled, participant, investigators and assessors-blinded 
proof-of-concept trial, as illustrated in figure 1.
Identification of participants
Patients from respiratory outpatient clinics in the Royal 
Victoria Infirmary, Freeman Hospital and patient iden-
tification centres (PIC) in primary care in the area of 
Newcastle upon Tyne, UK are included in this trial. 
In addition, Queen Elizabeth Hospital in Gateshead, 
Darlington Memorial Hospital and University Hospital 
of North Durham, UK are also used as PIC sites. The 
start date for this trial is August 2015 and the original 
funder proposed end date is December 2018. In the 
above centres, patients with COPD are screened to deter-
mine their eligibility. Patients are then approached by a 
member of the research team who provides the partic-
ipant with study information and a patient information 
sheet (PIS). Patients' details (eligibility, reason for ineli-
gibility, contact details as well as appointment dates and 
times) are entered on a password protected screening 
log. Patients are contacted by a member of the research 
team and those who agree to participate in the study 
are given an appointment to attend for their baseline 
visit and subsequent visits at 1 month, 3 months and 6 
months in the National Institute of Health Research 
Clinical Research Facility in the Royal Victoria Infirmary, 
Newcastle upon Tyne, UK. The inclusion and exclusion 
criteria are displayed in box 1.
Intervention
Aspirin is administered as a 75 mg once-daily dose and 
ticagrelor administered as a 90 mg twice-daily dose for 
6 months. The bases for the investigational medicinal 
Figure 1 APPLE COPD study flow chart. CIMT, carotid intima-media thickness; FEV1, forced expiratory volume in 1s; FVC, 
forced vital capacity; hsCRP, high-sensitivity C reactive protein; IL-6, interleukin-6; MPO, myeloperoxidase; PIC, patients’ 
identification centre; TNF, tumour necrosis factor.
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products (IMPs) are Brilique (ticagrelor) 90 mg (compo-
sition: ticagrelor, mannitol, dibasic calcium phosphate, 
sodium starch glycolate, hydroxypropyl cellulose and 
magnesium stearate) and placebo tablets (lactose mono-
hydrate, microcrystalline cellulose and magnesium stea-
rate) supplied by AstraZeneca as well as commercially 
available aspirin 75 mg tablets (aspirin, maize starch, 
E553). MODEPHARMA (London, UK) is responsible 
for arranging the aspirin placebo manufacturing and 
labelling/randomised packaging of all IMPs and final 
qualified person (QP) release for clinical trial use. Active 
and placebo study medication are provided as a 3-month 
supply. Study medication is prescribed by the principal 
investigator or the named study clinical research associate 
according to the protocol, and dispensed to the patient 
according to local pharmacy policy. Patients in possession 
of their study medication shall return all trial supplies in 
their original packaging (even if empty) to the research 
team at 3-month and 6-month follow-up visits.
Study drug must be discontinued if, participant develops 
thrombolysis in myocardial infarction (TIMI) major bleed, 
decides they no longer wish to continue or cessation of 
study drug is recommended by the investigator. The investi-
gator also has the right to withdraw patients from the study 
drug in the event of intercurrent illness, AEs, serious AEs, 
suspected unexpected serious adverse reactions, protocol 
violations, administrative reasons or other reasons.
All patients will be reviewed by the research team 
at 1 month, 3 months and at 6 months to ensure and 
enhance the likelihood of good compliance. Compliance 
with study medication will be assessed by checking and 
recording the remaining number of capsules after each 
visit/at the final visit. Study drug accountability will be 
assessed and documented by local pharmacy. The clin-
ical team will also perform a quick review of any returned 
study medication at each study visit to identify any obvious 
compliance concerns and address these immediately with 
the participant.
Participants will continue to take medications for 
other conditions as normal, and a complete listing of all 
concomitant medication received during the treatment 
phase are recorded in the electronic case report forms 
(eCRF).
prIMAry outCoME
The primary outcome for this study consists of inhi-
bition (binary response) ofASPI and ADP-induced 
platelet function at 6 months. ADP response is defined as 
ADP <46 and ASPI response is defined as ASPI <40. For 
patients randomised to ticagrelor, response is according 
to ADP response and for patients randomised to aspirin, 
response is evaluated according to the ASPI response.
sECondAry outCoMEs
We will evaluate the following secondary outcomes 
measures: changes in inflammatory markers including 
fibrinogen, hsCRP, TNF-α, IL-6, MPO from baseline to 
6 months; changes in CIMT and non-invasive measures of 
vascular stiffness from baseline to 6 months; and changes in 
quality of life using questionnaires (EQ5D-5L, St. George’s 
Respiratory Questionnaire for COPD (SGRQ-C)) at base-
line and at 6 months. In addition, although this study is not 
powered to measure hard end points, at the time of the start 
of this study there were not adequate information available 
in the literature on the CV event rate. Therefore, in addi-
tion in our study we recorded the occurrence of repeat 
hospitalisation, angina, myocardial infarction or death at 
6 months. However, we have noted the incidence of CV 
events described in the more recently published SUMMIT 
trial, which evaluated the effect of inhaled corticosteroid 
and long-acting beta-agonist on survival in patients with 
moderate COPD and heightened CV risk.15
sAfEty outCoMEs
The downside of dual APT is the occurrence of bleeding, 
which in itself can lead to excess mortality.26 27 There-
fore, we monitor and evaluate the bleeding events very 
carefully in our trial. The primary safety outcome will be 
rates of major and minor bleeding as defined by the TIMI 
scale28 and the Bleeding Academic Research Consortium 
(BARC) definition.29 In addition, given ticagrelor can 
lead to increase in dyspnoea due its adenosine-mediated 
effects, we also monitor decline in FEV1, FVC and Medical 
box 1 Inclusion and exclusion criteria
Inclusion criteria:
1. Abnormal spirometry with  forced expiratory volume   in 1 s 
(FEV1)<80% and FEV1/forced vital capacity ratio <70% of predicted.
2. Smoking history that is 10  pack-years or greater (current or 
ex-smokers can be included).
3. Have capacity to consent.
Exclusion criteria:
1. Age<18 years.
2. Any condition that is being concurrently treated through antico-
agulation or antiplatelet therapy (APT) including aspirin (any form 
of aspirin) or ticagrelor (atrial fibrillation, deep vein thrombosis, 
valve prosthesis, recent myocardial infarction, use of drug-eluting 
stents).
3. Other specific contraindications to management with antiplatelet 
medication (bleeding risks, allergies).
4. Any contraindication for aspirin and ticagrelor use.
5. Other concurrent terminal illnesses with life expectancy <1 year 
(congestive cardiac failure, carcinoma, etc).
6. Current involvement in another clinical trial or exposure to another 
investigational medicinal product within the previous 30 days.
7. Chronic obstructive pulmonary disease with an atypical cause (eg, 
A1-antitrypsin deficiency).
8. Patients who are unable to provide informed consent.
9. Planned/expected major surgery within next 9 months where APT 
would be ceased.
10. Pregnancy, planned pregnancy or current breast feeding.
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Research Council (MRC) dyspnoea scale (breathlessness) 
as a safety outcome measure.
baseline data collection
At the baseline research clinic, the patients undergo the 
following procedures by the research team: QRISK2 score 
using an online calculator (http://www. qrisk. org/); 
30 mL blood sample to measure platelet reactivity and 
biomarker levels; lung function tests (FEV1 and FVC) 
using spirometry; ultrasound scan to measure CIMT; 
vascular stiffness using the Vicorder device (Skidmore 
Medical, Bristol, UK) and quality of life (EQ5D-5L and 
SGRQ-C) and MRC dyspnoea scale. All data are collected 
in eCRF using MACRO (Elsevier, Amsterdam, The Neth-
erlands). No patient identifiable data are entered and 
user access is password protected.
platelet function testing
High on-treatment platelet reactivity despite use of P2Y12 
antagonists is associated with adverse cardiac events.30 
A previous study showed that patients with  COPD who 
underwent percutaneous coronary intervention have 
higher ‘on-treatment’ platelet reactivity compared with 
patients with no COPD and suggested that this could 
contribute to the high CV mortality in these patients.31 
Aspirin inhibits platelet-mediated atherothromboem-
bolic events by irreversible inhibition of platelet cycloo-
xygenase-1 with subsequent prevention of the synthesis 
of the potent pro-aggregatory prostanoid thromboxane 
A2. Despite aspirin therapy, a large number of patients 
continue to experience atherothromboembolic events, 
so-called 'aspirin treatment failure', and this is multifac-
torial in aetiology. Approximately 10% do not respond 
appropriately to aspirin in a phenomenon known as 
'aspirin resistance'.32 The beneficial effect of aspirin for 
the primary prevention of CVD is modest and occurs 
at doses of 100 mg or less per day. Older adults seem to 
achieve a greater relative myocardial infarction benefit.33 
In the APPLE COPD trial, we evaluate the effect of APT 
in patients with COPD on platelet function. Importantly, 
this trial will allow us to evaluate compliance of therapy 
in this patient cohort. Of note, in the SUMMIT trial 
23%–29% of patients withdrew investigational product.15
Multiple electrode aggregometry enables rapid assess-
ment of platelet function using a whole blood sample. 
The signal reaction in multiplate analyser is triggered by 
the adhesion of activated platelets to the surfaces of the 
sensor electrodes, which induces an increase of electrical 
resistance. Each test cell incorporates two pairs of sensors 
serving as a built-in quality control.34 Multiplate analyser, 
consumables and reagents have been provided by Roche 
Diagnostics (Roche Diagnostics, West Sussex, London, 
UK). The multiplate analyser has an electronic pipette 
and by using a predefined pipette programme, 300 µL of 
whole blood from a citrate sample is diluted with warm 
normal saline (0.9%). For each sample, three assays of 
platelets reactivity are carried out: (1) ASPI test using 
arachidonic acid to determine the level of inhibition of 
cyclooxygenase-induced platelet function in accordance 
with the proposed aspirin effect; (2) ADP test to deter-
mine inhibition of ADP-induced platelets aggregation, 
which is in accordance with the hypothesised ticagrelor 
effect; (3) the Thrombin receptor-activating peptide 
(TRAP) test to determine platelet reactivity via stimula-
tion of the thrombin receptors is used to ensure the reli-
ability of the results given by the analyser, given patients 
will not be on any glycoprotein IIb/IIIa antagonists to 
inhibit platelet reactivity. The results are represented by a 
graphic curve of aggregation (AU)/min. The parameters 
of the results are: the velocity (AU/min), the aggregation 
(AU) and area under the curve expressed in AU×min or 
U (10 AU×min=1U).
Inflammatory biomarker analysis
Neurohormonal activation and systemic inflammation 
have been suspected to play a significant role in increasing 
the risk of CV disease.35–37 The exact mechanism by which 
systemic inflammation develops in patients with  COPD 
is not yet well understood. Some studies have suggested 
this could be due to the release of cytokines and oxygen 
radicals from the lungs into the systemic circulation, 
while others attribute this to the hyperactivity of the 
sympathetic nervous system leading to the activation of 
a peripheral inflammatory response.38 Biomarkers of 
systemic inflammation, including fibrinogen, CRP,36 IL-6, 
IL-8 and TNF-α,39 40 are higher in patients with stable 
COPD as compared with control subjects. The release of 
oxygen radicals may promote the oxidation of low-density 
lipoproteins and the formation of foam cells increasing 
the risk of CAD as well as inducing a systemic immune 
response.41 Given ticagrelor has previously been shown to 
have anti-inflammatory properties20 and also associated 
with reduced mortality following pulmonary AEs and 
sepsis21 and the fact that patients with  COPD have height-
ened inflammatory burden, we wanted to evaluate the 
effect of ticagrelor on the various inflammatory markers 
and CV disease burden in this trial.
Blood samples are collected at baseline, 1-month and 
6-month visits and tested for full blood count, lipid profile, 
hsCRP, fibrinogen, TNF-α, MPO, IL-6 and microRNA.
vascular stiffness
Arterial stiffness is another emerging predictor of the risk 
of CVD. Arterial pulse wave velocity (aPWV) is a widely 
used method of assessing arterial stiffness. A recently 
published meta-analysis of 27 longitudinal studies (>20 000 
participants) revealed a strong and positive relationship 
between aPWV and CV morbidity and mortality.42 The 
severity of emphysema was found to be independently 
associated with higher arterial stiffness,43 44 which could 
possibly be one of the mechanisms of increased risk of 
CVD in patients with  COPD independent of systemic 
inflammation. Some studies showed aPWV to be higher 
in patients with  COPD but not to be related to the level 
of inflammatory markers; however, age and blood pres-
sure were found to be determinants of aPWV in these 
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patients.45 46 We evaluated the baseline vascular stiffness 
in patients and also repeated these measures at 1 month 
and 6 months. It is unlikely that APT will lead to signif-
icant effect on the vascular stiffness. However given the 
anti-inflammatory properties of ticagrelor, we wish to 
explore this further in our study.
aPWV is measured using Vicorder device (Skidmore 
Medical), which relies on pressure sensors. This is a non-in-
vasive and reproducible method that can be performed at 
the bedside using Vicorder software (Skidmore Medical). 
Participants will be asked to lie on a bed at approximately 
45 degrees angle with blood pressure cuffs placed on the 
arm, upper leg and neck to measure brachial, femoral 
and carotid artery pressures, respectively. The distance 
between the sternal notch to the femoral cuff will be used 
in assessment of aPWV and from sternal notch to umbi-
licus to assess brachiofemoral pulse wave analysis (PWA). 
PWA assessment includes measurement of the pulse pres-
sure (PP), augmentation index, which is the difference 
between the first and second systolic peaks relative to PP 
and is used as a surrogate measure of arterial stiffness,47 
and the augmentation pressure in addition to ankle 
brachial pressure index. PP (systolic minus diastolic blood 
pressure) can also be used as a surrogate measure of arte-
rial stiffness. A PP wave is generated by each contraction 
of the left ventricle and it precedes blood flow down the 
aorta. In normal subjects, the PP wave propagates down 
the aorta to the peripheral arterioles and capillaries. At 
the level of the capillaries, part of this wave is transmitted 
down these small blood vessels and is responsible for the 
continuous low pulsatile blood flow to the tissues; while 
part of the wave is reflected back to the left ventricle. The 
stiffer the arteries and mainly the aorta the faster this 
reflected wave travels back to the left ventricle causing an 
increase in the afterload and systolic blood pressure and 
may result in reduction in the diastolic coronary blood 
flow.48 49
Carotid intima-media thickness
A previous study that compared hsCRP and CIMT in 
newly diagnosed untreated patients with  COPD versus 
subjects without COPD showed CIMT and hsCRP to be 
significantly higher in the COPD group (p<0.05).50 A 
large study which assessed the association between hsCRP, 
fibrinogen and CIMT in 2502 patients with  COPD 
concluded that these two inflammatory biomarkers are 
related to CIMT in a multivariate-adjusted analysis and 
smoking was associated with a higher CIMT in men.35 In 
the APPLE trial once again given the potential anti-in-
flammatory effects of ticagrelor, we explored the effect 
of APT on CIMT in patients with  COPD. Long-term 
follow-ups will be required to show significant impact on 
CIMT. However, this study was not planned as a long-term 
follow-up study but a study to understand the basic mech-
anisms that might help us guide in the planning of future 
studies.
CIMT is measured using Xario XG ultrasound machine 
with a vascular probe to obtain ECG gated images of both 
the right and left common carotid arteries. The visualised 
CIMT of both near and far walls are measured at approx-
imately 1 cm proximal to the carotid bulb using manual 
calibration method. Readings of maximum and average 
CIMT are obtained.
Lung function testing
One of the hallmarks of COPD is an accelerated decline 
in lung function, as measured by spirometry. Inflamma-
tion, oxidative stress and other pathways are hypothesised 
to be important in this deterioration. We wanted to eval-
uate if APT therapy impacting the inflammatory burden 
in the lungs will lead to improvement in lung function 
measured using spirometry. Spirometry is performed by a 
trained member of the research team at baseline (unless 
previously conducted in the 30 days prior to baseline visit 
during a routine clinic appointment) and at 6-month visit 
using a Vitalograph Gold Standard Bellows Spirometer.
Quality of life questionnaires
Quality of life is impaired in patients with COPD.51 
Improvement in lung function could potentially lead to 
improvement in quality of life in these patients. Two ques-
tionnaires are used to assess the quality of life at baseline, 
1 month and 6 months visits. These are the SGRQ-C and 
the EQ5D-5L. SGRQ-C is the shorter version of the SGRQ, 
which is a research tool that has been shown to have good 
discriminative properties and is responsive to therapeutic 
trials; strong correlation has been demonstrated between 
SGRQ-C scores and the severity of COPD.51 52 The 
EQ5D-5L Questionnaire assesses the self-reported health 
status at the time of completion of the questionnaire.53 In 
the present study, we will be able to evaluate the changes 
in quality of life in the different treatment groups.
follow-up
Compliance with study medications and the occurrence 
of AEs are continuously assessed throughout the study 
at 1 month, 3 months and 6 months. In addition, all 
study-related procedures described above are measured 
at 1 month and at 6 months. Schedule of events is shown 
in table 1.
sample size calculation
For each research question, a Fleming A’Hern54 early 
phase design is used to investigate the roles of (i) aspirin 
and (ii) ticagrelor as being individually worthy of further 
investigation. To determine whether aspirin or ticagrelor 
is likely to meet a minimum level of efficacy worthy of 
further investigation, the Fleming A’Hern54 design 
requires specification of the response rates at 6 months 
above and below which would indicate whether to proceed 
or not proceed to a phase III trial. These rates have 
been chosen based on a study by Perl et al,55 who report 
a response rate for ticagrelor and prasugrel at 1 month 
of 100% and 91.3%, respectively in a non-randomised 
comparison. The APPLE COPD trial design assumes 
a 6-month rate would be high, similar to the reported 
1-month rate of Perl et al. and as such assumes a response 
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rate to reject either treatment (p0) <65% and a response 
rate to investigate either treatment further (p1) >80%. 
The design of the trial focuses on demonstrating that a 
response rate of 80% is plausible and that the response 
rate is at least >65%. For each research question, the justi-
fication to investigate either treatment further is based 
on observing a minimum number of responses in each 
interventional arm, referred to as the critical number. 
Due to minimal background evidence, the control arms 
provide a direct and unbiased benchmark. As an early 
phase trial, the error levels have been inflated beyond 
those expected for a definitive large phase III study but 
restricted to an acceptable level for an early phase trial 
of 12% alpha (type 1) and 12% beta (type 2). With these 
stated parameters, the target recruitment is calculated as 
50 patients per arm for each comparison within the 2×2 
design: (i) aspirin (n=50) versus no aspirin (n=50); (ii) 
ticagrelor (n=50) versus no ticagrelor (n=50), as below. 
Fifty was the smallest number which satisfies the design 
criteria above. In this trial, the ‘no aspirin’ and ‘no tica-
grelor groups’ provide an unbiased control benchmark 
response rate due to minimal background evidence. As 
this trial is investigating outcomes at 6 months following 
randomisation, the sample size is adjusted for an antici-
pated 15% dropout rate within the 6-month timeframe, 
rounded to a target recruitment of 120 patients. The 
estimated dropout rate will be monitored throughout 
the recruitment period. The Fleming A’Hern design54 
would indicate no further investigation of each treatment 
individually if the observed number of responses in each 
intervention arm (for aspirin and ticagrelor separately) is 
less than the critical number.
recruitment
Patients with  COPD will be identified in PIC. The PIC 
will provide information about the study by handing 
out the PIS to eligible patients and/or will advertise the 
opportunity to participate in the study via posters in their 
waiting rooms. The patients will be invited to participate 
in the study by the research team (PIs, clinical research 
associate or research nurse) after being given adequate 
information on the study.
Table 1 Schedule of events
No. Time
Pre-COPD-
OPD
V1 V2* V3 V4 V5
COPD-OPD 
visit
Baseline 
research 
clinic†
1 month 
research 
clinic† 
3 months 
research 
clinic† 
6 months 
research 
clinic† 
  1 PIS sent through post, along with routine clinic 
invite letter
(CRA, RN)
X
  2 Identify potential patients willing to participate 
(CRA, RN)
X
  3 Informed consent (CRA, CI, PI) X X
  4 QRISK2 calculate (CRA, RN) X
  5 Medical history (CRA, RN) X
Concomitant medications check by CRA/RN X X X X
  6 Routine bloods for FBC, urea, electrolytes, 
cholesterol, inflammatory markers‡, Multiplate test 
(CRA, RN)
X X X
  7 Vascular stiffness (CRA) X X
  8 Carotid intima-media thickness (CRA) X X
  9 Lung function test (this can be done in recent 
COPD-OPD visit window) (CRA, RN)
X X
  10 Questionnaires (SGRQ, EQ5D-5L) (CRA, RN) X X X
  11 Randomisation (CRA, RN) X
  12 Study medication dispensed (CRA, RN) X X
  13 Review study medications (CRA, RN) X X X
  14 Adverse events (CRA, RN) X X X
  15 Collect clinical events data (CRA, RN) X
*We will allow ±1 week for visits.
†Newcastle National Institute of Health Research Clinical Research Facility, Level 6, Leazes Wing, Royal Victoria Infirmary, Queen 
Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.
‡Including interleukin-6, myeloperoxidase, tumour necrosis factor-α, microRNA.
COPD, chronic obstructive pulmonary disease; CRA, clinical research associate; FBC, full blood count; PI, principal investigator; PIS, 
patient information sheet; RN, research nurse; SGRQ, St. George’s Respiratory Questionnaire. 
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randomisation
Consenting patients who fulfil the inclusion and exclu-
sion criteria are randomised using the Newcastle Clin-
ical Trials Unit secure web-based system. Participants are 
allocated into one of four groups to receive either aspirin 
plus placebo, ticagrelor plus placebo, aspirin plus tica-
grelor or placebo only, using a stratified blocked treat-
ment allocation (permuted random blocks of variable 
length). The randomisation list was generated by an 
independent statistician. Stratification is based on the 
important confounder of age (dichotomised as ≤65 years, 
>65 years). Each patient is allocated a unique trial number 
at the point of randomisation. Treatment allocation is 
double-blinded and as such the randomisation procedure 
generates a treatment pack number for each participant 
that links to the corresponding allocated study drug. This 
automated procedure will produce a pharmacy prescrip-
tion including the patient’s unique trial number and 
treatment pack number to ensure the study pharmacist 
dispenses the correct trial medication.
blinding
Assignment to either active or placebo arm will be 
blinded to both the participant and investigators/assessor 
(double-blind). The need for emergency unblinding is 
felt unlikely and will preferably be avoided. In case of 
emergency (bleeding), it will be assumed that patient is 
on dual APT. In the event of bleeding on such medica-
tions in routine practice the therapies are simply withheld. 
No specific therapies are instituted in this setting after 
initiating simple support measures to reduce bleeding 
including pressure. In the event of any bleeding deemed 
clinically significant by the healthcare professional seeing 
a study participant (either as part of the study team or as 
part of emergency services), the patient will be advised to 
provide the patient participation card. This will contain 
both emergency contact numbers for the study team (to 
be contacted if deemed needed) and also clear instruc-
tions on stopping the trial medications.
data collection and management
The strategy of reviewing all patients at 1, 3 and 6 
months will promote participant retention and complete 
follow-up. Should a patient withdraw from study drug 
only, efforts will be made to continue to obtain follow-up 
data, with the permission of the patient. Data will be 
entered directly onto a data management system by the 
research team and stored on the Newcastle Clinical Trials 
Unit’s MACRO database, provided by Elsevier’s Software 
as a service system MACRO is a secure validated clinical 
data management system. Data will be handled, comput-
erised and stored in accordance with the Data Protection 
Act 1998. No participant identifiable data will leave the 
study site. The quality and retention of study data will be 
the responsibility of the chief investigator. All study data 
will be retained in accordance with the latest directive on 
Good Clinical Practise (GCP) (2005/28/EC) and local 
policy.
patient and public involvement
In this trial, patient and public were not involved.
statistical analysis
Descriptive statistics will be tabulated by compara-
tive group and overall. Continuous measures will be 
presented as mean (SD) or median (IQR). As a 2×2 facto-
rial design, the primary analyses are based on a compar-
ison of: aspirin versus no aspirin and ticagrelor versus 
no ticagrelor. For each analysis, the primary outcome 
measure is platelet response rate measured at 6 months 
(1 month response rate is assessed as a secondary 
outcome measure). Response rate will be calculated on 
the intention-to-treat (ITT) dataset as the total number 
of patients responding as a proportion of all patients 
randomised (patients with missing primary outcome data 
are classed as non-responders) and reported descriptively 
as both a rate and unadjusted OR with 95% CIs. A sensi-
tivity analysis will be carried out on the modified ITT 
dataset. Response rate will be calculated on the modified 
ITT dataset as the total number of patients responding 
as a proportion of all patients randomised with a primary 
outcome measurement at 6 months. Any patients who 
are not assessable at 6 months will be classed as missing 
and removed. A sensitivity analysis will be carried out on 
the per protocol (PP) set where the response rate will 
be calculated on the PP dataset as the total number of 
patients responding as a proportion of the number of 
patients within each comparative group of the PP dataset. 
Any patients with missing primary outcome data, who are 
protocol deviators are removed. Secondary analyses will 
be based on adjusted OR of the treatment effect adjusted 
by the stratification variables (age) estimated in a multi-
variable logistic regression model and 1 month reported 
response rate. AEs will be reported descriptively as the 
number of events, and number of unique patients expe-
riencing an AE as a proportion of the total number of 
patients starting treatment. Biological outcome measures 
will be presented graphically and descriptively as medians 
(with IQRs). Patient quality of life will be scored according 
to instructions for the individual questionnaires and 
reported graphically and descriptively as means (with 
SD). Due to the randomisation process, platelet reactivity 
is assumed balanced at randomisation. Previous literature 
is minimal and as such this trial is designed using early 
phase methodology with the aim to investigate levels of 
activity worthy of further investigation in later studies. As 
such, the trial is not powered for any hypothesis testing.
trial monitoring
Monitoring of study conduct and data collected will be 
performed by a combination of central review and site 
monitoring visits to ensure the study is conducted in accor-
dance with GCP. Study site monitoring will be undertaken 
by Newcastle Clinical Trials Unit following risk-based 
assessment approved by sponsor. The main areas of focus 
will include consent, serious AEs, essential documents in 
study files, drug accountability and management.
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The trial may be prematurely discontinued on the basis 
of new safety information, or for other reasons given by 
the Trial Oversight Committee and/or Trial Management 
Group, sponsor, regulatory authority or ethics committee 
concerned. The Trial Oversight Committee will advise on 
whether to continue or discontinue the study and make 
a recommendation to the sponsor. If the study is prema-
turely discontinued in terms of patient recruitment, 
participants enrolled to date will be informed, no further 
participants will be randomised and enrolled participants 
will be followed up.
Harms
Most AEs and adverse drug reactions that occur in this 
study, whether they are serious or not, will be expected 
treatment-related effects due to the drugs used in this 
study. All non-serious adverse reactions will be recorded 
at 6 months follow-up, and serious AEs will be recorded 
throughout the duration of the trial until 4 weeks after 
trial therapy is stopped. The Medicines and Healthcare 
products Regulatory Agency (MHRA) and main Research 
Ethics Committee (REC) will be notified by the sponsor 
via the electronic MHRA reporting system of all suspected 
unexpected serious adverse reaction (SUSARs) occurring 
during the study according to the following timelines; 
fatal and life-threatening within 7 days of notification 
and non-life threatening within 15 days. All investigators 
will be informed of all SUSARs occurring throughout the 
study on a case-by-case basis.
Auditing
The study is subject to inspection and audit by Newcastle 
upon Tyne Hospitals NHS Foundation Trust under their 
remit as sponsor, and other regulatory bodies to ensure 
adherence to GCP. The investigator(s)/institutions will 
permit trial-related monitoring, audits, REC review and 
regulatory inspection(s), providing direct access to source 
data/documents.
Ethics
The conduct of this study will be in accordance with the 
recommendations for physicians involved in research on 
human subjects adopted by the Declaration of Helsinki 
(1996). Clinical Trial Authorisation from the MHRA and 
NHS R&D approval (Newcastle upon Tyne Hospitals NHS 
Foundation Trust) were also obtained prior to commence-
ment of the study. Information sheets (see online supple-
mentary appendix) are provided to all eligible subjects 
and written informed consent obtained prior to any study 
procedures.
protocol amendments
Protocol amendments were agreed on by Newcastle upon 
Tyne Hospitals NHS Trust and AstraZeneca, and approved 
by the North East-Tyne and Wear South Research Ethics 
Committee prior to implementation. In the initial 
protocol version, we had intended to continue collecting 
the AEs data up to 1 year. However, in the latest approved 
protocol amendment version we decided to collect data 
up to 6 months only.
Consent
One of the research team members will approach the 
patients to see if they are agreeable to take part in the 
study. Informed consent discussions will be undertaken 
by appropriate site staff (as per delegation log), including 
medical staff and research nurses, with opportunity for 
participants to ask any questions. Following receipt of 
information about the study, participants will be given 
reasonable time to decide whether or not they would like 
to participate. Those wishing to take part will provide 
written informed consent by signing and dating the study 
Patient Informed Consent Form, which will be witnessed 
and dated by a member of the research team with docu-
mented, delegated responsibility to do so.
Confidentiality
All personal data will be regarded as strictly confidential. 
To preserve anonymity, any data leaving the site will iden-
tify participants by their initials and a unique study iden-
tification code only. The study will comply with the Data 
Protection Act, 1998. All study records and Investigator 
Site Files will be kept at site in a locked filing cabinet with 
restricted access. All laboratory samples will be labelled 
with a unique study identification number and patient 
date of birth only (linked in anonymised form).
Access to data
Chief investigator, co-investigators and the trial team will 
have access to the data sets, which are password protected.
Ancillary and post-trial care
The Newcastle upon Tyne Hospitals NHS Foundations 
Trust is sponsor and through the sponsor, National 
Health Service (NHS) indemnity is provided in respect 
of potential liability and negligent harm arising from 
study management. Both sites within this study are hospi-
tals within Newcastle upon Tyne Hospitals NHS Founda-
tions Trust and NHS indemnity is provided in respect of 
potential liability and negligent harm arising from study 
conduct. Indemnity in respect of potential liability arising 
from negligent harm related to study design is provided 
by NHS schemes for those protocol authors who have 
their substantive contracts of employment with the NHS 
and by Newcastle University Insurance schemes for those 
protocol authors who have their substantive contract of 
employment with the Newcastle University.
dissemination
The data will be the property of the chief investigator 
and co-investigators. Publication will be the responsi-
bility of the chief investigator and published under the 
authorship agreed with the co-investigators and the trial 
team who fulfil the ICMJE criteria for authorship. It is 
planned to publish this study in peer-reviewed journals 
and to present data at national and international meet-
ings. Results of the study will also be reported to the 
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sponsor and funder. Participants will be informed about 
their treatment and their contribution to the study at the 
end of the study, including a lay summary of the results.
ConCLusIon
This trial is the first study to evaluate APT specifically tica-
grelor in patients with  COPD with no history of CAD. 
This study will enable a detailed understanding of the 
baseline CV disease burden in patients with COPD and 
the response rate to APT in terms of platelets inhibition. 
In addition, the effect of APT on inflammatory and CV 
disease burden is explored. This will help us to very care-
fully plan future large-scale multicentre primary preven-
tion study among patients with COPD evaluating hard 
end points such as myocardial infarction and mortality.
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